Presentation is loading. Please wait.

Presentation is loading. Please wait.

What we will review this lecture: Receptor Tyrosine Kinase signalling: PI3K Pathway – AKT, PDK1, PTEN RTK Signalling in Cancer Historical description of.

Similar presentations


Presentation on theme: "What we will review this lecture: Receptor Tyrosine Kinase signalling: PI3K Pathway – AKT, PDK1, PTEN RTK Signalling in Cancer Historical description of."— Presentation transcript:

1 What we will review this lecture: Receptor Tyrosine Kinase signalling: PI3K Pathway – AKT, PDK1, PTEN RTK Signalling in Cancer Historical description of BCR-ABL

2 Friedrich Grimminger, Ralph T. Schermuly & Hossein A. Ghofrani. Nature Reviews Drug Discovery 9, 956-970

3

4

5

6

7 CML: Chronic Myelogenous Leukemia – Asymptomatic at time of diagnosis Abnormal white blood cell count Stable for 3 – 5 years followed by “Blast Crisis” Fatal within 3 – 6 months of Blast crisis 20% of all leukemia's 5000 cases per year in US (compare with 180,000 lung cancer cases)

8 CML: Chronic Myelogenous Leukemia – All CML cells harbor Philadelphia chromosome 1960: Peter Nowell David Hungerford Nowell P, Hungerford D. "A minute chromosome in chronic granulocytic leukemia." Science 1960;132:1497.

9 1973: Janet D. Rowley Discovered t(9;22) Rowley JD. "A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [letter]". Nature 1973;243:290–3.

10

11

12

13

14

15

16 c-Abl Kinase Domain Structure

17 STI-571

18

19 www.cmlsupport.com


Download ppt "What we will review this lecture: Receptor Tyrosine Kinase signalling: PI3K Pathway – AKT, PDK1, PTEN RTK Signalling in Cancer Historical description of."

Similar presentations


Ads by Google